Miguel Virseda-Chamorro

Dr. Miguel Virseda-Chamorro

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
ANA ISABEL COBO-CUENCAANA ISABEL COBO-CUENCA
ANA ISABEL COBO-CUENCA
ASAntonio Sampietro-Crespo
Antonio Sampietro-Crespo
MVMiguel Virseda-Chamorro
Miguel Virseda-Chamorro
NMNoelia María Martín-Espinosa
Noelia María Martín-Espinosa

4 June 2020 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
Javier C. AnguloJavier C. Angulo
Javier C. Angulo
MVMiguel Virseda-Chamorro
Miguel Virseda-Chamorro
IAIgnacio Arance
Ignacio Arance
SRSonia Ruiz
Sonia Ruiz
AOAntonio Ojea
Antonio Ojea
FCFrancisco Cruz
Francisco Cruz

21 February 2013 in International Journal Of Impotence Research
Verified
Journal Article
Closed access
PDF file
MVMiguel Virseda-Chamorro
Miguel Virseda-Chamorro
JSJ Salinas-Casado
J Salinas-Casado
ALA M Lopez-Garcia-Moreno
A M Lopez-Garcia-Moreno
ANA ISABEL COBO-CUENCAANA ISABEL COBO-CUENCA
ANA ISABEL COBO-CUENCA
MEM Esteban-Fuertes
M Esteban-Fuertes

21 September 2012 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
MVMiguel Virseda-Chamorro
Miguel Virseda-Chamorro
JSJesús Salinas
Jesús Salinas
MEManuel Esteban
Manuel Esteban
SMSantiago Méndez
Santiago Méndez

19 October 2015 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
MVMiguel Virseda-Chamorro
Miguel Virseda-Chamorro
JSJesus Salinas‐Casado
Jesus Salinas‐Casado
PGPablo Gutiérrez‐Martín
Pablo Gutiérrez‐Martín
MMManuel de la Marta‐García
Manuel de la Marta‐García
ALAntonio López‐García‐Moreno
Antonio López‐García‐Moreno
MFManuel Esteban Fuertes
Manuel Esteban Fuertes

19 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AUAne Ullate
Ane Ullate
IAIgnacio Arance
Ignacio Arance
MVMiguel Virseda-Chamorro
Miguel Virseda-Chamorro
SRSonia Ruiz
Sonia Ruiz
JSJuliusz Jan Szczesniewski
Juliusz Jan Szczesniewski
Javier C. AnguloJavier C. Angulo
Javier C. Angulo
(1) Background: Male stress incontinence in patients with previously treated urethral or bladder neck stricture is a therapeutic challenge. The efficacy and safety of the adjustable trans-obturator male system (ATOMS) in these patients is unknown. (2) Methods: All patients with primary ATOMS implants in our institution between 2014 and 2021 were included. The outcomes of patients with previously treated urethral or bladder neck stricture (≥6 months before ATOMS implant) and stable 16Ch urethral caliber were compared to those without a history of stricture. The primary endpoint was the dry patient rate, defined as the pad test ≤ 20 mL/day, and complication rate, including device removal. The secondary variable was self-perceived satisfaction using the Patient Global Impression of Improvement (PGI-I) scale. Wilcoxon rank sum test, Fisher’s exact test and logistic regression were performed. (3) Results: One hundred and forty-nine consecutive patients were included, twenty-one (14%) previously treated for urethral or bladder neck stricture (seven urethroplasty, nine internal urethrotomy and five bladder neck incision). After ATOMS adjustment, 38% of the patients with treated stricture were continent compared to 83% of those without (p < 0.0001). After weighted matched observations using propensity score pairing, the proportion of continent patients without a previous stricture was 56% (p = 0.236). Complications occurred in 29% of the patients with stricture and in 20% of those without (p = 0.34). The severity of the complications was distributed evenly among the groups (p = 0.42). Regarding self-perceived satisfaction with the implant, 90% of the patients with stricture perceived the results satisfactorily (PGI-I 1–3) compared to 97% of the rest (p = 0.167). Stricture was associated with radiotherapy (p < 0.0001) and time from prostatectomy to implantation (p = 0.012). There was a moderate correlation between previous stricture and the severity of incontinence, both evaluated according to the 24-h pad test (Rho = 0.378; p < 0.0001) and the ICIQ-SF questionnaire (Rho = 0.351; p < 0.0001). Multivariate analysis for the factors predictive of failure after ATOMS adjustment revealed previous stricture (OR 4.66; 95% CI 1.2–18.87), baseline 24-h pad test (per 100 mL, OR 1.28; 95% CI 1.09–1.52) and final cushion volume (per mL, OR 1.34; 95% CI 1.19–1.55). This model predicted dryness with an AUC of 92%. After the PSMATCH procedure using a propensity score, the model remained unchanged, with the previous stricture (OR 8.05; 95% CI 1.08–110.83), baseline 24-h pad test (per 100 mL, OR 1.53; 95% CI 1.15–2.26) and final cushion volume (per mL, OR 1.45; 95% CI 1.17–2) being independent predictors and an AUC of 93%. (4) Conclusions: ATOMS can be used to treat male stress incontinence in patients with a history of stricture, although the effectiveness of the device is reduced. On the other hand, the security and perceived satisfaction were equivalent for both groups.